Estrogen vs. Fosamax for Bone Health: Why HRT Can Be More Powerful Than Bisphosphonates

Today I want to talk about estrogen and bone health versus bone drugs, specifically bisphosphonates like Fosamax (alendronate). I ran into a study while preparing a talk on hormones and bone health, and it did a great job showing a few important things.

First, it highlights how powerful hormone replacement therapy (HRT) can be for bone—sometimes even more powerful than a common first-line osteoporosis drug. Second, it shows that dose matters. And third, it hints that how you replace hormones—the type, the route, and the schedule—can change the outcome.

This is also a good reminder that the “fear era” after the Women’s Health Initiative shaped how hormones were prescribed for decades. That history still affects care today. So if you are deciding between estrogen and a bone drug, or if you are already on one and wondering how they compare, this topic matters.

Why this study matters (even though it’s from the 1990s)

When I review research, I look at a few things right away:

• When was it done?
• Is it still relevant?
• Where was it published?
• How strong is the design?

This study was done in the late 1990s, which is a very important window. HRT was widely used then. This was before the Women’s Health Initiative (WHI) changed public fear around estrogen. So the study reflects a time when hormone prescribing was common and less constrained by fear.

It was also published in the New England Journal of Medicine, which is a high-impact journal with strict peer review. That does not make it perfect, but it is a strong signal that the methods and reporting were taken seriously.

And lastly, the trial was big. It included over 1,100 women. That matters because many hormone trials are small. Large studies make it easier to see real patterns and reduce noise.

The study setup: Fosamax doses vs. hormone therapy

The study was titled:

“Prevention of Bone Loss with Alendronate (Fosamax) in Postmenopausal Women Under 60 Years of Age.”

So this was not a “severe osteoporosis in older age” group. This was younger postmenopausal women. That is key. It is a population where prevention and early intervention matter a lot.

They compared several groups:

• Placebo
• Fosamax 2.5 mg daily
• Fosamax 5 mg daily
• Hormone therapy (estrogen + progestin)

The reason this study is so useful is that they included hormone therapy in a drug trial. That is unusual. It was likely a drug-company funded trial. So I don’t know why they did it. But I’m glad they did, because it gives us direct comparison data.

They also ran the study in multiple centers:

• Two in the U.S.
• Two in Europe

That matters because hormone prescribing patterns were different between the U.S. and Europe.

The outcomes: DEXA changes and side effects

The main outcome was DEXA changes over two years. They also tracked adverse events.

Drug trials often have clean outcomes. That is part of why they are powerful. You get a lot of participants, clear endpoints, and structured reporting.

This study looked at DEXA changes in:

• Spine (mostly trabecular bone)
• Hip (more cortical bone)
• Forearm (mostly cortical bone)

That’s important because trabecular and cortical bone behave differently. Many interventions show bigger changes in trabecular bone. Cortical bone often changes slower.

‍

What hormone therapy did in this study (and why Europe did better)

Here is an important part of the trial: the U.S. hormone therapy was not the same as the European hormone therapy.

U.S. hormone therapy (static dosing)

This was the common pattern in the U.S. in that era:

• Conjugated equine estrogen (CEE) (Premarin)
• Medroxyprogesterone acetate (MPA) (Provera / PremPro)
• Taken daily in a static pattern

These are the same drug types that were used in the Women’s Health Initiative later on.

European hormone therapy (more “physiologic” pattern)

Europe used a different approach in this trial:

• Oral estradiol (bioidentical estrogen, but oral)
• A shifting dose through the month
• A synthetic progestin given for part of the cycle
• A more “rhythmic” or cycle-like pattern

This is important because it starts to mimic natural hormone rhythms instead of being flat and static.

The key results (simple numbers)

Graphs look nice, but numbers matter. Here are the results the study showed over two years.

Spine bone density

• Placebo: -1.8%
• Fosamax 5 mg: +3.5%
• U.S. hormone therapy: +4.0%
• European hormone therapy: +5.1%

If you look at difference-from-placebo:

• Fosamax 5 mg: +5.3%
• U.S. hormones: +5.8%
• European hormones: +6.9%

That is a clear signal: hormones outperformed Fosamax for spine density.

Hip bone density

• Placebo: -1.6%
• Fosamax 5 mg: +1.3%
• U.S. hormone therapy: +1.8%
• European hormone therapy: +3.2%

Difference-from-placebo:

• U.S. hormones: +3.4%
• European hormones: +4.8%

This is a bigger deal than it looks. Hip bone tends to move less. Seeing a larger jump here matters, especially because hip fractures are so life-changing.

Forearm bone density (mostly cortical bone)

• Placebo: -2.5%
• Fosamax 5 mg: -1.4%
• U.S. hormone therapy: -0.3%
• European hormone therapy: +0.5%

Forearm changes tend to be smaller. But the pattern is still important. Hormones at least stabilized cortical bone better than the drug.

What this tells us: why HRT can beat bone drugs

When you step back, this study points to three big drivers:

1) Dose matters

After WHI, the common rule became: “lowest dose, shortest time.” That pushed estrogen doses lower and lower. For some women, low-dose estrogen helps symptoms but does not protect bone enough.

Bone has a threshold effect. Many people need estradiol above a certain level to get meaningful bone receptor impact. There is research suggesting thresholds in the range of 60–80 pg/mL for some bone benefits, though the exact number can vary person to person.

If you never reach the threshold, you may still lose bone even while “on HRT.”

2) Route and form matter

The older studies used forms that we often avoid today:

• Synthetic progestins can carry higher risk than micronized progesterone
• Some synthetic progestins interact with receptors in ways we don’t want
• Oral estrogens can change liver signaling, which can affect clot risk and other factors

In modern practice, many clinicians prefer:

• Transdermal estradiol (patch or topical)
• Oral micronized progesterone when needed
• Custom dosing based on labs, symptoms, and goals

This reduces some risks and often improves tolerability.

3) Timing matters (static vs. physiologic patterns)

This study also hints at something we see elsewhere: physiologic, rhythmic dosing patterns often outperform flat, static regimens for bone.

The “push-pull” of hormones can be more powerful for bone signaling than a flat line. That is not to say every woman should cycle. Some should not. But it matters that we stop pretending all hormone plans are the same.

‍

The bigger message: Fosamax is not a long-term plan

Even if you believe Fosamax works well short-term, there is a problem:

• Bisphosphonates are often limited to a defined use window
• Many patients need drug holidays
• Long-term strategy gets murky

Hormone therapy, when appropriate, can be a more durable long-term lever for bone, muscle, and metabolic health. This is not a “drugs bad” post. It is a “plan matters” post.

This study even showed something ironic: a pharmaceutical-sponsored trial still demonstrated that hormone therapy outperformed the drug.

What to do if you’re choosing between hormones and bone drugs

If you are trying to decide what makes sense, start with data. Do not guess.

• Know your baseline bone density (DEXA or REMS)
• Understand your risk level (fractures, family history, labs)
• Understand your hormone status and symptoms
• Know that dose, route, and timing change outcomes

If you want help with HRT specifically, we run a Hormone Masterclass that goes deep on the pros, cons, risks, and styles of therapy. We keep it separate from the Bone Masterclass because there is too much nuance to squeeze into one session.

And if you want a community and weekly Q&A support, our HealthSpan Nation is built for that. This is where people can ask questions, learn from others, and access content that helps them build a full plan.

FAQ

Is estrogen better than Fosamax for osteoporosis?

In this study, hormone therapy outperformed Fosamax for bone density outcomes, especially in the spine. That does not mean it is best for every person. Your risk profile matters.

Does low-dose HRT protect bone?

Sometimes. But many people still lose bone on low-dose regimens. Dose and blood levels can matter.

Why does Europe dosing look better in this trial?

The European regimen was more rhythmic and used oral estradiol in a more cycle-like pattern. That may have created a stronger bone signal.

Can men use estrogen for bone health?

Men need estradiol too, but they usually get it from testosterone conversion. Over-suppressing that conversion can increase bone risk.

What’s the best approach if I’m unsure?

Start with screening and labs. Then build a plan that matches your risk and your goals. Avoid one-size-fits-all protocols.

Medical Disclaimer

This content is for educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult your licensed healthcare professional before making medical decisions, changing medications, starting supplements, or beginning a new exercise program.

‍